Status:

ACTIVE_NOT_RECRUITING

Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia

Lead Sponsor:

Unity Health Toronto

Collaborating Sponsors:

National Institute of Neurological Disorders and Stroke (NINDS)

Conditions:

Hereditary Hemorrhagic Telangiectasia

Eligibility:

All Genders

Brief Summary

This study is one of the three projects of an NIH Rare Disease Clinical Research Consortium. A "consortium" is a group of centres sharing information and resources to perform research. The consortium ...

Detailed Description

4\. Study Design and Methods In conjunction with the DMCC, we will construct a relational database and web-based data collection instrument; see Table 1 showing the sites that will contribute to this ...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Definite clinical HHT diagnosis (at least 3 Curacao criteria)or genetic diagnosis of HHT or
  • Definite clinical HHT diagnosis (at least 3 Curacao criteria) or genetic diagnosis of HHT and Presence of Brain Arteriovenous Malformation
  • Able to provide informed consent
  • Curacao criteria:
  • spontaneous recurrent nosebleeds;
  • mucocutaneous telangiectasia at characteristic sites (lips, oral cavity or the nose);
  • visceral involvement such as pulmonary, hepatic or CNS BAVM; and (d) an affected first degree relative by same criteria.
  • Willingness
  • Willingness to participate in the study and ability to give informed consent
  • Exclusion Criteria:
  • Patients not complying with Inclusion criteria

Exclusion

    Key Trial Info

    Start Date :

    April 8 2010

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    June 30 2025

    Estimated Enrollment :

    2272 Patients enrolled

    Trial Details

    Trial ID

    NCT01158807

    Start Date

    April 8 2010

    End Date

    June 30 2025

    Last Update

    April 8 2025

    Active Locations (19)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 5 (19 locations)

    1

    Barrow Neurological Institute

    Phoenix, Arizona, United States, 85013

    2

    University of Arkansas for Medical Sciences

    Little Rock, Arkansas, United States, 72205

    3

    David Geffen School of Medicine at University of California, Los Angeles

    Los Angeles, California, United States, 90095

    4

    University of California, San Francisco

    San Francisco, California, United States, 94110

    Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia | DecenTrialz